Evidence map›Paper›PMID 30131588›Full record

ArticleThe pharmacogenomics journal2019

A non-functional galanin receptor-2 in a multiple sclerosis patient.

Sheila Garcia-Rosa, Daniela Bb Trivella, Vanessa D Marques, Rodolfo B Serafim, José Gc Pereira, Julio Cc Lorenzi, Greice A Molfetta, Paulo P Christo, Guilherme S Olival, Vania Bt Marchitto and 24 more

Abstract read
PubMed Publisher
In one paragraph

Article in The pharmacogenomics journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Intranasal Delivery of a Methyllanthionine-Stabilized Galanin Receptor-2-Selective Agonist Reduces Acute Food Intake.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 11 institutions in 2 countries.

Sheila Garcia-RosaLab. of Medical Genomics, AC Camargo Cancer Center, São Paulo, SP, Brazil.
Daniela Bb TrivellaBrazilian Biosciences National Laboratory (LNBio), Center for Research in Energy and Material (CNPEM), Campinas, SP, Brazil.ORCID http://orcid.org/0000-0002-7505-2345
Vanessa D MarquesDepartment of Neurosciences, Clinical Neuroimmunology Division, Medical School of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.
Rodolfo B SerafimDepartment of Cellular and Molecular Biology, Medical School of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.
José Gc PereiraBrazilian Biosciences National Laboratory (LNBio), Center for Research in Energy and Material (CNPEM), Campinas, SP, Brazil.
Julio Cc LorenziDepartment of Genetics, Ribeirão Preto Medical School, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.
Greice A MolfettaDepartment of Genetics, Ribeirão Preto Medical School, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.
Paulo P ChristoCurso de Pós-Graduação, Santa Casa de Belo Horizonte, Belo Horizonte, MG, Brazil.
Guilherme S OlivalNeurosciences Research Group, Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, SP, Brazil.
Vania Bt MarchittoNeurosciences Research Group, Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, SP, Brazil.
Doralina G BrumDepartment of Neurology, Psychology and Psychiatry, School of Medicine of Botucatu, University of State of São Paulo (UNESP), Botucatu, SP, Brazil.
Thais S SabedotDepartment of Genetics, Ribeirão Preto Medical School, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.
Houtan NoushmehrDepartment of Genetics, Ribeirão Preto Medical School, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.
Alessandro S FariasNeuroimmunology Unit, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil.
Leonilda Mb SantosNeuroimmunology Unit, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil.
José A Nogueira-MachadoCurso de Pós-Graduação, Santa Casa de Belo Horizonte, Belo Horizonte, MG, Brazil.
Jorge Es SouzaInstituto Metrópole Digital, Federal University of Rio Grande do Norte, Natal, RN, Brazil.
Camila M RomanoLab. Virology (LIM52), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil.
Rodrigo M CondeDepartment of Neurosciences, Clinical Neuroimmunology Division, Medical School of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.
Antonio C SantosDepartment of Neurosciences, Clinical Neuroimmunology Division, Medical School of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.
Carlos T GuerreiroDepartment of Neurosciences, Clinical Neuroimmunology Division, Medical School of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.
Willem H SchreuderLab. of Medical Genomics, AC Camargo Cancer Center, São Paulo, SP, Brazil.
Frederico O Gleber-NettoLab. of Medical Genomics, AC Camargo Cancer Center, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0001-7847-9902
Maria AmorimLab. of Medical Genomics, AC Camargo Cancer Center, São Paulo, SP, Brazil.
Renan ValierisLaboratory of Bioinformatics and Computational Biology, AC Camargo Cancer Center, Sao Paulo, Brazil.
Israel Tojal da SilvaLaboratory of Bioinformatics and Computational Biology, AC Camargo Cancer Center, Sao Paulo, Brazil.
Wilson A SilvaDepartment of Genetics, Ribeirão Preto Medical School, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.
Diana N NunesLab. of Medical Genomics, AC Camargo Cancer Center, São Paulo, SP, Brazil.
Paulo Sl OliveiraBrazilian Biosciences National Laboratory (LNBio), Center for Research in Energy and Material (CNPEM), Campinas, SP, Brazil.ORCID http://orcid.org/0000-0002-1287-8019
Valeria ValenteSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, SP, Brazil.
Maria Augusta ArrudaCAPES-University of Nottingham Programme in Drug Discovery, Queen's Medical Centre University of Nottingham, Nottingham, NG7 2UH, United Kingdom.ORCID http://orcid.org/0000-0002-0828-9430
Stephen J HillCell Signalling Research Group, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom. Steve.Hill@nottingham.ac.uk.
Amilton A BarreiraDepartment of Neurosciences, Clinical Neuroimmunology Division, Medical School of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, SP, Brazil. aabarrei@fmrp.usp.br.
Emmanuel Dias-NetoLab. of Medical Genomics, AC Camargo Cancer Center, São Paulo, SP, Brazil. emmanuel@accamargo.org.br.
AC Camargo Hospital · BRUniversidade de Ribeirão Preto · BRUniversidade de São Paulo · BRUniversity of Nottingham · GBBrazilian Center for Research in Energy and Materials · BRFaculdade de Ciências Médicas da Santa Casa de São Paulo · BRGrupo Santa Casa de Belo Horizonte · BRUniversidade Estadual de Campinas (UNICAMP) · BRUniversidade Estadual Paulista (Unesp) · BRHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRInstituto Federal do Rio Grande do Norte · BR

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Brazilian Federal Agency for the Support and Evaluation of Graduate Education) 23038.007775/2014-98Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Brazilian Federal Agency for the Support and Evaluation of Graduate Education) 7350-15-5Fundação de Amparo à Pesquisa do Estado de São Paulo (São Paulo Research Foundation) 2015/07925-5Fundação de Amparo à Pesquisa do Estado de São Paulo (São Paulo Research Foundation) 2016/06488-3Ministry of Science, Technology and Innovation | Conselho Nacional de Desenvolvimento Científico e Tecnológico (National Council for Scientific and Technological Development) 480138/2013-3
6 · The paper itself

Abstract

Multiple Sclerosis (MS) is an inflammatory neurodegenerative disease that affects approximately 2.5 million people globally. Even though the etiology of MS remains unknown, it is accepted that it involves a combination of genetic alterations and environmental factors. Here, after performing whole exome sequencing, we found a MS patient harboring a rare and homozygous single nucleotide variant (SNV; rs61745847) of the G-protein coupled receptor (GPCR) galanin-receptor 2 (GALR2) that alters an important amino acid in the TM6 molecular toggle switch region (W249L). Nuclear magnetic resonance imaging showed that the hypothalamus (an area rich in GALR2) of this patient exhibited an important volumetric reduction leading to an enlarged third ventricle. Ex vivo experiments with patient-derived blood cells (AKT phosphorylation), as well as studies in recombinant cell lines expressing the human GALR2 (calcium mobilization and NFAT mediated gene transcription), showed that galanin (GAL) was unable to stimulate cell signaling in cells expressing the variant GALR2 allele. Live cell confocal microscopy showed that the GALR2 mutant receptor was primarily localized to intracellular endosomes. We conclude that the W249L SNV is likely to abrogate GAL-mediated signaling through GALR2 due to the spontaneous internalization of this receptor in this patient. Although this homozygous SNV was rare in our MS cohort (1:262 cases), our findings raise the potential importance of impaired neuroregenerative pathways in the pathogenesis of MS, warrant future studies into the relevance of the GAL/GALR2 axis in MS and further suggest the activation of GALR2 as a potential therapeutic route for this disease.

Indexed as

AdultAmino Acid SequenceBase SequenceCase-Control StudiesCell LineFemaleGalaninHEK293 CellsHumansMultiple SclerosisPhosphorylationPolymorphism, Single NucleotideReceptor, Galanin, Type 2Signal TransductionYoung AdultGalaninReceptor, Galanin, Type 2

Identifiers

PMID30131588
OpenAlexW2888438092

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.